Predicting ADMET properties for commercially available anticancer drugs

Abstract

Drug discovery and development is a tedious process which involves high man power, costly chemicals and resources. Failure of drugs at late stage clinical trials is the common problem that occurs at current scenario. Though tremendous input has been given to discover new drugs, overcoming the drug failures and occurrence of adverse side effects need to be rectified. Predicting Absorption, Distribution, Metabolism and Excretion (ADME) properties at early stage with in silico tools would be much promising.In this paper, commercially available anticancer drugs were taken and their ADME properties were predicted with SWISS ADME. The results shows that most of the drugs possess lower solubility, low GL absorption and lower penetration to blood brain barrier. The obtained results could be a model to develop new drugs and to design anticancer drugs that eventually prevent late stage clinical trials.